cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aeglea Biotherapeutics Inc
18 own
28 watching
Current Price
$0
$0
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
8.52M
52-Week High
52-Week High
1.56
52-Week Low
52-Week Low
0.1251
Average Volume
Average Volume
0.14M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization8.52M
icon52-Week High1.56
icon52-Week Low0.1251
iconAverage Volume0.14M
iconDividend Yield--
iconP/E Ratio--
What does the Aeglea Biotherapeutics Inc do?
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company s lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Read More
How much money does Aeglea Biotherapeutics Inc make?
News & Events about Aeglea Biotherapeutics Inc.
Ticker Report
1month ago
Investment analysts at StockNews.com initiated coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research report issued on Wednesday. The firm set a hold rating on the biotechnology companys stock. AGLE has been the subject of a number of other ...
PR Newswire
1month ago
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of...
Zolmax
4 months ago
StockNews.com began coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE Get Rating) in a research note released on Monday morning. The firm issued a hold rating on the biotechnology companys stock. AGLE has been the topic of several other research reports. Piper Sandler increased their target ...
PR Newswire
4 months ago
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency PR Newswire AUSTIN, Texas, Jan. 6, 2023 Streamlining of organization to focus on near-term deliverables...
Zolmax
6 months ago
Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE Get Rating) saw a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 611,000 shares, an increase of 17.8% from the October 15th total of 518,700 shares. Based on an average daily trading ...
Frequently Asked Questions
Frequently Asked Questions
What is Aeglea Biotherapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aeglea Biotherapeutics Inc shares?
plus_minus_icon
How can I buy Aeglea Biotherapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aeglea Biotherapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aeglea Biotherapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aeglea Biotherapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aeglea Biotherapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aeglea Biotherapeutics Inc?
plus_minus_icon
What percentage is Aeglea Biotherapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aeglea Biotherapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0
(-1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$0.30
$0.00 (-1.14 %)
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.29
$0.00 (1.38 %)
Humanigen Inc
Humanigen Inc
$0.15
$0.00 (2.45 %)
I-Mab
I-Mab
$3.17
$0.14 (4.62 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
ONCTERNAL THERAPEUTICS INC
ONCTERNAL THERAPEUTICS INC
$0.30
$0.00 (-1.14 %)
Finch Therapeutics Group Inc
Finch Therapeutics Group Inc
$0.29
$0.00 (1.38 %)
Humanigen Inc
Humanigen Inc
$0.15
$0.00 (2.45 %)
I-Mab
I-Mab
$3.17
$0.14 (4.62 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00